Global Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market 2025 by Company, Regions, Type and Application, Forecast to 2031
Description
According to our (Global Info Research) latest study, the global Treatment of Chemotherapy-Induced Nausea in Cancer Patients market size was valued at US$ 2377 million in 2024 and is forecast to a readjusted size of USD 2125 million by 2031 with a CAGR of -1.6% during review period.
Chemotherapy-induced nausea and vomiting (CINV) is a common side-effect of many cancer treatments. Nausea and vomiting are two of the most feared cancer treatment-related side effects for cancer patients and their families.
The chemotherapy-induced nausea and vomiting (CINV) treatment market is driven by the increasing prevalence of cancer and the growing adoption of effective antiemetic therapies. Chemotherapy often causes nausea and vomiting, adversely affecting the quality of life of cancer patients. The rise in cancer incidence and the need for better supportive care contribute to market growth as healthcare providers and patients seek reliable CINV treatments to manage these distressing side effects. Moreover, advancements in antiemetic drug development and the introduction of combination therapies have improved treatment efficacy and patient outcomes. However, the market also faces challenges, including the individual variability in CINV response and the need for tailored treatment approaches. Additionally, addressing the cost of antiemetic drugs and ensuring accessibility to patients can pose obstacles for widespread adoption. To succeed, companies must focus on research and development to offer innovative and patient-centric CINV treatments, collaborate with oncologists to optimize treatment regimens, and address the challenges to meet the increasing demand for effective and well-tolerated antiemetic therapies for cancer patients undergoing chemotherapy.
This report is a detailed and comprehensive analysis for global Treatment of Chemotherapy-Induced Nausea in Cancer Patients market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Treatment of Chemotherapy-Induced Nausea in Cancer Patients market size and forecasts, in consumption value ($ Million), 2020-2031
Global Treatment of Chemotherapy-Induced Nausea in Cancer Patients market size and forecasts by region and country, in consumption value ($ Million), 2020-2031
Global Treatment of Chemotherapy-Induced Nausea in Cancer Patients market size and forecasts, by Type and by Application, in consumption value ($ Million), 2020-2031
Global Treatment of Chemotherapy-Induced Nausea in Cancer Patients market shares of main players, in revenue ($ Million), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Treatment of Chemotherapy-Induced Nausea in Cancer Patients
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Treatment of Chemotherapy-Induced Nausea in Cancer Patients market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Heron Therapeutics, Merck, Eisai, Mundipharma, Qilu Pharma, Teva, Novartis, Roche, Mylan, Baxter, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Treatment of Chemotherapy-Induced Nausea in Cancer Patients market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
5-HT3 Inhibitors
NK1 Inhibitors
Other
Market segment by Application
Acute CINV
Delayed CINV
Breakthrough CINV
Others
Market segment by players, this report covers
Heron Therapeutics
Merck
Eisai
Mundipharma
Qilu Pharma
Teva
Novartis
Roche
Mylan
Baxter
GSK
Helsinn
Southwest Pharma
Haisco
Sun Pharma
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Treatment of Chemotherapy-Induced Nausea in Cancer Patients product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Treatment of Chemotherapy-Induced Nausea in Cancer Patients, with revenue, gross margin, and global market share of Treatment of Chemotherapy-Induced Nausea in Cancer Patients from 2020 to 2025.
Chapter 3, the Treatment of Chemotherapy-Induced Nausea in Cancer Patients competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2020 to 2031
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2020 to 2025.and Treatment of Chemotherapy-Induced Nausea in Cancer Patients market forecast, by regions, by Type and by Application, with consumption value, from 2026 to 2031.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Treatment of Chemotherapy-Induced Nausea in Cancer Patients.
Chapter 13, to describe Treatment of Chemotherapy-Induced Nausea in Cancer Patients research findings and conclusion.
Chemotherapy-induced nausea and vomiting (CINV) is a common side-effect of many cancer treatments. Nausea and vomiting are two of the most feared cancer treatment-related side effects for cancer patients and their families.
The chemotherapy-induced nausea and vomiting (CINV) treatment market is driven by the increasing prevalence of cancer and the growing adoption of effective antiemetic therapies. Chemotherapy often causes nausea and vomiting, adversely affecting the quality of life of cancer patients. The rise in cancer incidence and the need for better supportive care contribute to market growth as healthcare providers and patients seek reliable CINV treatments to manage these distressing side effects. Moreover, advancements in antiemetic drug development and the introduction of combination therapies have improved treatment efficacy and patient outcomes. However, the market also faces challenges, including the individual variability in CINV response and the need for tailored treatment approaches. Additionally, addressing the cost of antiemetic drugs and ensuring accessibility to patients can pose obstacles for widespread adoption. To succeed, companies must focus on research and development to offer innovative and patient-centric CINV treatments, collaborate with oncologists to optimize treatment regimens, and address the challenges to meet the increasing demand for effective and well-tolerated antiemetic therapies for cancer patients undergoing chemotherapy.
This report is a detailed and comprehensive analysis for global Treatment of Chemotherapy-Induced Nausea in Cancer Patients market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Treatment of Chemotherapy-Induced Nausea in Cancer Patients market size and forecasts, in consumption value ($ Million), 2020-2031
Global Treatment of Chemotherapy-Induced Nausea in Cancer Patients market size and forecasts by region and country, in consumption value ($ Million), 2020-2031
Global Treatment of Chemotherapy-Induced Nausea in Cancer Patients market size and forecasts, by Type and by Application, in consumption value ($ Million), 2020-2031
Global Treatment of Chemotherapy-Induced Nausea in Cancer Patients market shares of main players, in revenue ($ Million), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Treatment of Chemotherapy-Induced Nausea in Cancer Patients
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Treatment of Chemotherapy-Induced Nausea in Cancer Patients market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Heron Therapeutics, Merck, Eisai, Mundipharma, Qilu Pharma, Teva, Novartis, Roche, Mylan, Baxter, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Treatment of Chemotherapy-Induced Nausea in Cancer Patients market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
5-HT3 Inhibitors
NK1 Inhibitors
Other
Market segment by Application
Acute CINV
Delayed CINV
Breakthrough CINV
Others
Market segment by players, this report covers
Heron Therapeutics
Merck
Eisai
Mundipharma
Qilu Pharma
Teva
Novartis
Roche
Mylan
Baxter
GSK
Helsinn
Southwest Pharma
Haisco
Sun Pharma
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Treatment of Chemotherapy-Induced Nausea in Cancer Patients product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Treatment of Chemotherapy-Induced Nausea in Cancer Patients, with revenue, gross margin, and global market share of Treatment of Chemotherapy-Induced Nausea in Cancer Patients from 2020 to 2025.
Chapter 3, the Treatment of Chemotherapy-Induced Nausea in Cancer Patients competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2020 to 2031
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2020 to 2025.and Treatment of Chemotherapy-Induced Nausea in Cancer Patients market forecast, by regions, by Type and by Application, with consumption value, from 2026 to 2031.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Treatment of Chemotherapy-Induced Nausea in Cancer Patients.
Chapter 13, to describe Treatment of Chemotherapy-Induced Nausea in Cancer Patients research findings and conclusion.
Table of Contents
114 Pages
- 1 Market Overview
- 2 Company Profiles
- 3 Market Competition, by Players
- 4 Market Size Segment by Type
- 5 Market Size Segment by Application
- 6 North America
- 7 Europe
- 8 Asia-Pacific
- 9 South America
- 10 Middle East & Africa
- 11 Market Dynamics
- 12 Industry Chain Analysis
- 13 Research Findings and Conclusion
- 14 Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
